EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Characterizing clinically recognized hypertrophic cardiomyopathy in six European countries using real-world data

Marta Alcalde-Herraiz iD, Antonella Delmestri, Hezekiah Omulo, Elvira Bräuner, Susanne Bruun, Raeleesha Norris, Annika Vivirito, Alexander Harms, Jakov Vuković, Ivan Pristaš, Anamaria Jurčević, Marko Čavlina und 14 weitere

ESC Heart Failure · 2026

DOI: 10.1093/eschf/xvag218 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift ESC Heart Failure, 2026. Verfasst von Marta Alcalde-Herraiz und 25 weiteren Autor:innen. Beteiligte Einrichtung: Health Data Sciences, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, …. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Medicines Agency, DARWIN.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy. However, large-scale epidemiological evidence remains scarce due to challenges in real-world disease recognition. This study aimed to characterize clinically recognized HCM and obstructive HCM (oHCM) across six European countries regarding prevalence, demographics, and clinical characteristics.

Methods

We conducted a retrospective cohort study using routinely collected healthcare data from six European countries, all mapped to the Observational Medical Outcomes Partnership (OMOP) Common Data Model within the DARWIN EU® network: CPRD-GOLD (UK), DK-DHR (Denmark), InGef RDB (Germany), NAJS (Croatia), NLHR (Norway), and SIDIAP (Spain). Clinically recognized HCM was defined based on recorded diagnoses captured in routine healthcare data, rather than on imaging-, haemodynamic-, or genotype-confirmed population screening. Adults (≥18 years) with a first recorded HCM or oHCM diagnosis after 2010 were included. We estimated annual period prevalence and described recorded comorbidities, diagnostic measurements, and treatments before, at, and after diagnosis.

Results

Among 40 277 individuals with HCM, 12 363 (31%) were first diagnosed with oHCM. Females were older than males at diagnosis (median 67–78 vs 57–68 years). Annual period prevalence increased over time, ranging from 0.04% (95% Confidence interval: 0.04–0.05) to 0.24% (0.23–0.24) in recent years. Prevalence was higher in males, but differences diminished among those aged ≥80 and with oHCM. Cardiovascular comorbidities were frequently recorded before and at the time of first diagnosis, especially hypertension, cardiac arrhythmias, ischaemic heart disease, and heart failure. Beta-blockers, diuretics, and angiotensin-converting enzyme inhibitors were the most common treatments. Most comorbidities and treatments were recorded over a year before HCM diagnosis.

Conclusions

An increase in the prevalence of clinically recognized HCM across Europe was observed over time. This trend is likely multifactorial and may reflect changes in disease recognition, clinical practice, demographics, database-related factors, and potentially the underlying disease burden. Cardiovascular comorbidities and treatments were frequently recorded prior to diagnosis, which may suggest that some patients would benefit from increased diagnostic awareness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicHumansMaleFemaleEuropeRetrospective StudiesPrevalenceMiddle AgedAgedAdultFollow-Up Studies

Stichwörter der Autor:innen

EuropeHypertrophic cardiomyopathyObservational studiesObstructive hypertrophic cardiomyopathyPrevalenceReal-world Data

Autor:innen und Institutionen

  • Health Data Sciences, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, OX3 7LD Oxford, England.
  • Data Analytics Center, Danish Medicines Agency, Copenhagen, Denmark.
  • Data Science/Health Services Research, InGef-Institute for Applied Health Research Berlin GmbH, Berlin, Germany.
  • Medical Informatics and Biostatistics Division, Croatian National Institute of Public Health, Zagreb, Croatia.
  • PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, University of Oslo, Oslo, Norway.
  • Department of Child Health and Development, Norwegian Institute of Public Health, Oslo, Norway.

ORCID-Profile: Marta Alcalde-Herraiz, Edward Burn, Albert Prats-Uribe

Förderung

  • European Medicines Agency
  • DARWIN

Zitieren

APA

Alcalde-Herraiz, M., Delmestri, A., Omulo, H., Bräuner, E., Bruun, S., Norris, R., Vivirito, A., Harms, A., Vuković, J., Pristaš, I., Jurčević, A., Čavlina, M., Jezidžić, A., Ivanko, P., Hayati, S., Trinh, N. T. H., Nordeng, H. M. E., Duarte-Salles, T., Palomar-Cros, A., …, & Saura-Lázaro, A. (2026). Characterizing clinically recognized hypertrophic cardiomyopathy in six European countries using real-world data. ESC Heart Failure. https://doi.org/10.1093/eschf/xvag218

Vancouver

Alcalde-Herraiz M, Delmestri A, Omulo H, Bräuner E, Bruun S, Norris R, et al. Characterizing clinically recognized hypertrophic cardiomyopathy in six European countries using real-world data. ESC Heart Failure. 2026. doi:10.1093/eschf/xvag218

BibTeX
@article{AlcaldeHerraiz2026,
  author = {Alcalde-Herraiz, Marta and Delmestri, Antonella and Omulo, Hezekiah and Bräuner, Elvira and Bruun, Susanne and Norris, Raeleesha and Vivirito, Annika and Harms, Alexander and Vuković, Jakov and Pristaš, Ivan and Jurčević, Anamaria and Čavlina, Marko and Jezidžić, Antea and Ivanko, Pero and Hayati, Saeed and Trinh, Nhung T H and Nordeng, Hedvig Marie Egeland and Duarte-Salles, Talita and Palomar-Cros, Anna and Giuliodori, Agustina and Gómez-Outes, Antonio and Vrijlandt, Patrick and Restrepo-Méndez, María Clara and Burn, Edward and Prats-Uribe, Albert and Saura-Lázaro, Anna},
  title = {Characterizing clinically recognized hypertrophic cardiomyopathy in six European countries using real-world data},
  journal = {ESC Heart Failure},
  year = {2026},
  doi = {10.1093/eschf/xvag218}
}
Kostenlos starten →